Summary & Overview
HCPCS G0483: Definitive Drug Test, 22+ Drug Classes
HCPCS Level II code G0483 represents a definitive laboratory drug test using advanced analytical methods (e.g., GC/MS, LC/MS) with stable isotope/internal standards and matrix-matched calibration, performed for 22 or more drug classes per day. This code captures high-complexity toxicology testing that distinguishes structural isomers and includes specimen validity assessment. Nationally, G0483 matters because it defines billing and clinical expectations for comprehensive confirmatory drug panels used in clinical care, forensic contexts, and substance use monitoring programs.
Key payers in typical coverage analyses include Aetna, Blue Cross Blue Shield plans, Cigna Health, UnitedHealthcare, and Medicare. Readers will find benchmarks and comparative guidance on how this code is described and applied across payer policies, an overview of clinical contexts where such definitive testing is used, and notes on coding nuances relevant to comprehensive, high-complexity toxicology panels. The publication summarizes reimbursement considerations, common modifiers submitted with complex laboratory services, and implications for lab operations and documentation when providing multi-class definitive testing.
Clinical & Coding Specifications
Clinical Context
A 38-year-old patient enrolled in an employer-sponsored substance use monitoring program presents to an outpatient laboratory for confirmatory toxicology testing after an initial positive point-of-care immunoassay. The specimen (urine) is collected under observed conditions, labeled, and transported to a certified laboratory. The laboratory performs a definitive, qualitative and/or quantitative testing panel using gas chromatography–mass spectrometry (gc/ms) or liquid chromatography–mass spectrometry (lc/ms) methods with stable isotope internal standards and matrix-matched calibration. Specimen validity testing (e.g., adulteration, dilution, substitution checks) is completed concurrently. Results are reported to the ordering clinician and the program case manager the same day or next business day, documenting identified parent drugs and metabolites across 22 or more drug classes, including any structural isomers distinguished by the method. Typical workflow steps: specimen collection and chain-of-custody documentation, accessioning, specimen validity testing, extraction and preparation, definitive lc/ms or gc/ms analysis with internal standards, method-specific calibration and quality control, data review by a laboratory director, and reporting of qualitative or quantitative results to the ordering provider and authorized payors or program administrators.
Coding Specifications
| Modifier | Description | When to Use |
|---|